Low Frequency of XXXX Using Cardiac Magnetic Resonance Imaging in an @entity2012 Contemporary Cohort.

@entity1 @entity296 @entity2012 @entity4346 @entity299 @entity2390 @entity2287 @entity1002
CONTEXT: @entity4346 ( @entity4346 ) and @entity296 are considered common findings of the @entity296 in echocardiography studies. OBJECTIVE: To evaluate the frequency of @entity4346 , @entity299 and @entity296 was undertaken in @entity1 with @entity2012 using cardiac magnetic resonance imaging (CMRi) before and after 12 months of @entity2390 long-acting repeatable treatment. @entity1 AND METHODS: Consecutive @entity1 with active @entity2012 submitted to biochemical analysis and CMRi before and after 12 months of treatment. Additionally, echocardiography was performed before treatment. RESULTS: Forty consecutive @entity1 were evaluated using CMRi at baseline and 30 @entity1 were reevaluated after 12 months of treatment. Additionally, 29 of these @entity1 were submitted to echocardiography. Using CMRi, the frequency of @entity4346 was 5%. The mean left ventricular mass index (LVMi) was 61.73    18.8 g/m(2). The mean @entity1002 ( @entity1002 ) was 61.85    9.2%, and all @entity1 had normal systolic function. Late @entity2287 enhancement was present in five @entity1 (13.5%), and one @entity1 (3.5%) had an increased extracellular volume. After treatment, 12 @entity1 (40%) had criteria for disease control. No clinically relevant differences in cardiac variables before and after treatment were observed. Additionally, there was no difference in LVMi and @entity1002 among @entity1 with and without disease control. Using echocardiography, 31% of the @entity1 had @entity4346 , mean LVMi was 117.8    46.3 g/m(2) and mean @entity1002 was 67.3    4.4%. All @entity1 had normal systolic function. CONCLUSIONS: We demonstrated by CMRi, the gold-standard method, that @entity1 with active @entity2012 might have a lower prevalence of @entity299 than previously reported.
